Quart Barry D 4

4 · Kiniksa Pharmaceuticals International, plc · Filed Jun 2, 2026

AI-generated summary of this filing

Updated Jun 2, 2026

Kiniksa (KNSA) Director Barry D. Quart Receives RSUs & Exercises Options

What Happened

Barry D. Quart, a director of Kiniksa Pharmaceuticals International, plc (KNSA), received equity awards and exercised an option on May 29, 2026. The filing shows grants of 12,158 RSUs and 2,026 RSUs (total 14,184 RSUs) that vested in full, and an exercise/conversion of 2,799 derivative shares (options). The filing also reports the disposition (surrender) of 2,799 shares on the same date. Prices for the grants and the reported dispositions are $0.00 in the filing (typical for RSU grants and net settlements).
This is primarily an award/vesting event (RSUs granted and vested). The option exercise followed by an equal-number disposition looks like a net settlement or surrender of shares (commonly used to cover taxes or exercise costs), not an open‑market sale for cash.

Key Details

Transaction date: May 29, 2026; Form 4 filed June 2, 2026 (no late‑filing flag shown in the provided excerpt).
Grants: 12,158 RSUs (F3/F4) and 2,026 RSUs (F1/F3/F4) — total 14,184 RSUs; each RSU converts to one Class A Ordinary Share when paid.
Option exercise: 2,799 derivative shares exercised/converted (code M); 2,799 shares simultaneously disposed (reported at $0.00).
Prices/values: Grants reported at $0.00 (typical for RSU awards); no cash sales or market value reported in the excerpt.
Shares owned after the transactions: not provided in the supplied filing details — see the full SEC filing for current beneficial ownership amounts.
Relevant footnotes:
- F1: Each RSU equals a contingent right to one Class A Ordinary Share.
- F2: The option vests monthly starting May 29, 2026 (grant date).
- F3/F4: The RSUs vested in their entirety on May 29, 2026 (vested in a single installment; no expiration).

Context

RSU grants and vesting are compensation events and do not necessarily signal buying or selling intent by the insider. The exercise plus immediate disposition of the same number of shares is often a net settlement or share surrender (commonly to cover taxes or exercise costs) rather than an open‑market sale. For complete details and any monetary amounts, consult the full Form 4 (Accession 0001384243-26-000012).

Form 4

Period: 2026-05-29

Director

Transactions

Exercise/Conversion
Class A Ordinary Share
[F1]
2026-05-29+2,799→ 15,345 total
Award
Share Option
[F2]
2026-05-29+12,158→ 12,185 total
Exercise: $48.38Exp: 2036-05-28→ Class A Ordinary Shares (12,158 underlying)
Award
Restricted Share Units
[F1][F3]
2026-05-29+2,026→ 2,026 total
→ Class A Ordinary Shares (2,026 underlying)
Exercise/Conversion
Restricted Share Units
[F1][F4]
2026-05-29−2,799→ 0 total
→ Class A Ordinary Shares (2,799 underlying)

Footnotes (4)

[F1]Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
[F2]The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.
[F3]The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.
[F4]The RSUs vested in a single installment on May 29, 2026; there was no expiration date for the RSUs.

Signature

/s/ Douglas Barry, Attorney-in-Fact|2026-06-02

1 file